Article Details

Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show

Retrieved on: 2020-12-14 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show. View article details on hiswai:

Excerpt

Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio ... “B-cell targeted therapy with anti-CD20 <b>monoclonal antibodies</b> has ...

Article found on: multiplesclerosisnewstoday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up